- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05158777
Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old
December 24, 2023 updated by: Shanghai Institute Of Biological Products
A Randomized, Blind, Controlled Clinical Trial to Evaluate Safety and Immunogenicity of Live Attenuated Varicella Vaccine After a Two-dose Vaccination Course in Healthy Population Aged ≥13 Years Old
This is a randomized, blind, controlled clinical trial of live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.
The purpose of this study is to evaluate the immunogenicity and safety of a two doses vaccination of investigational vaccine with 0,28 day and 0,56 day immunization schedule in population aged ≥13 years old.
Study Overview
Status
Completed
Conditions
Detailed Description
This study is a randomized, blind, controlled phase III clinical trial in population aged ≥13 years old.
The experimental vaccine will be manufactured by Shanghai Institute of Biological Products Co.,Ltd..
A total of 2480 subjects aged 13 years and older will be enrolled with 1240 subjects in 13~17 years old group and1240 subjects in 18 years and older group.
1240 subjects in each age group would be randomly divided into experimental group and control group according to 1:1 ratio, and subjects will receive two doses of vaccine with the immunization course of 0,28 days or 0,56 days.
In addition, 400 subjects from experimental group (100 subjects per subgroup) would be selected to collect blood at 3 and 5 years after immunization to evaluate immune persistence of live attenuated varicella vaccines.
Study Type
Interventional
Enrollment (Actual)
2480
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Dandan Chen
- Phone Number: 86-021-62750096
- Email: chendandan3@sinopharm.com
Study Contact Backup
- Name: Cheng Fu
- Phone Number: 86-021-62800991
- Email: fucheng@sinopharm.com
Study Locations
-
-
Henan
-
Zhenzhou, Henan, China
- Henan Provincial Center for Disease Prevention and Control
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
11 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy population aged 13 years and above;
- Proven legal identity;
- The subjects and/or guardians can understand and voluntarily sign the informed consent form (For subjects aged 13-17 years, both subjects and guardians need to sign the informed consent form).
Exclusion Criteria:
- Disease history or vaccine history of chickenpox or shingles;
- Have fever before vaccination, axillary temperature >37.0°C;
- Already pregnant (including a positive urine pregnancy test) or are breastfeeding, planning to get pregnant within 6 months;
- History of severe allergy and asthma, history of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioedema and abdominal pain;
- Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;
- Autoimmune disease or immunodeficiency / immunosuppression;
- Severe chronic diseases, severe cardiovascular diseases, hypertension (adult field measurement: SBP ≥140mmHg or diastolic blood pressure ≥90mmHg) that could not be controlled by drugs, diabetes, liver and kidney diseases, malignant tumors, etc.;
- Family history of psychosis,severe neurological disease (epilepsy, convulsions or twitching) or mental illness;
- Thyroid disease or history of thyroidectomy, asplenia, functional asplenia, asplenia or splenectomy resulting from any condition;
- Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;
- Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;
- History of alcohol or drug abuse;
- Receipt of blood products within in the past 6 months;
- Participating in other drug/vaccine clinical trial;
- Receipt of attenuated live vaccines in the past 28 days;
- Receipt of inactivated or subunit vaccines in the past 7 days;
- Onset of various acute or chronic diseases within 7 days prior to the study;
- According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental Group with the immunization course of 0,28 days or 0,56 days
1240 subjects (including 620 children aged 13-17 years and 620 adults aged 18 years and older) will receive two doses of experimental vaccine with the immunization course of 0,28 days or 0,56 days.
|
live varicella-zoster virus in 0.5 mL of sucrose, sodium chloride, potassium chloride, sodium glutamate, phosphate and injection water per injection
|
Active Comparator: Control Group
1240 subjects (including 620 children aged 13-17 years and 620 adults aged 18 years and older) will receive two doses of control vaccine with the immunization course of 0,28 days or 0,56 days.
|
live varicella-zoster virus in 0.5 mL of mannitol, dextrose tincture, sucrose, trehalose, human serum albumin and injection water per injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seroconversion rate of HI antibody
Time Frame: Day 42 after the whole schedule
|
The seroconversion rate of the antibody 42 days among all subjects after the second vaccination.
|
Day 42 after the whole schedule
|
GMT of HI antibody
Time Frame: Day 42 after the whole schedule
|
The GMT of the antibody 42 days among all subjects after the second vaccination.
|
Day 42 after the whole schedule
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seroprotection rate of HI antibody
Time Frame: Day 42 after the whole schedule
|
The seroprotection rate of the antibody 42 days among all subjects after the second vaccination.
|
Day 42 after the whole schedule
|
Incidence of adverse reactions within 30 minutes after each dose
Time Frame: Within 30 minutes after each dose
|
Incidence of adverse reactions within 30 minutes after each dose vaccination with immunization course of 0,28 days and 0,56 days.
|
Within 30 minutes after each dose
|
Incidence of adverse reactions within 0~28 days after each dose
Time Frame: Within 0~28 days after each dose
|
Incidence of adverse reactions within 0~28 days after each dose vaccination with immunization course of 0,28 days and 0,56 days.
|
Within 0~28 days after each dose
|
Incidence of serious adverse events
Time Frame: From vaccination to 6 months after the second vaccination
|
Incidence of serious adverse events from vaccination to 6 months after the second vaccination with immunization course of 0,28 days and 0,56 days
|
From vaccination to 6 months after the second vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yanxia Wang, Henan Provincial Center for Disease Control and Prevention
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 13, 2022
Primary Completion (Actual)
November 14, 2022
Study Completion (Actual)
November 14, 2022
Study Registration Dates
First Submitted
December 2, 2021
First Submitted That Met QC Criteria
December 2, 2021
First Posted (Actual)
December 15, 2021
Study Record Updates
Last Update Posted (Actual)
December 29, 2023
Last Update Submitted That Met QC Criteria
December 24, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020LP00094-III
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Varicella
-
The HIV Netherlands Australia Thailand Research...Chulalongkorn UniversityCompletedHIV Infections | Varicella-zoster VirusThailand
-
Merck Sharp & Dohme LLCCompletedVaricella Virus Infection
-
Wuerzburg University HospitalRecruitingVaccination; Infection | Zoster VaricellaGermany
-
University of Colorado, DenverCenters for Disease Control and PreventionWithdrawnPersistence of Varicella ImmunityUnited States
-
The University of Hong KongCompletedVaricella Zoster InfectionHong Kong
-
Zhuhai Trinomab Pharmaceutical Co., Ltd.Not yet recruiting
-
GlaxoSmithKlineCompleted
-
Merck Sharp & Dohme LLCCompleted
-
SK Chemicals Co., Ltd.CompletedImmunization; Infection | Varicella ZosterKorea, Republic of
-
GlaxoSmithKlineLudwig-Maximilians - University of MunichCompletedVaricella (Chickenpox) | Chickenpox VaccinesGermany
Clinical Trials on Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.
-
Sinovac (Dalian) Vaccine Technology Co., Ltd.Enrolling by invitation
-
Jiangsu Province Centers for Disease Control and...Beijing Minhai Biotechnology Co., LtdCompleted
-
GlaxoSmithKlineRecruiting
-
Jiangsu Province Centers for Disease Control and...CompletedAdverse Effect and Immunogenicity of VaccineChina
-
Beijing Minhai Biotechnology Co., LtdCompleted
-
GlaxoSmithKlineCompletedMeasles | Rubella | Mumps | Measles-Mumps-Rubella VaccineFinland, Thailand, United States, Spain, Czechia, Puerto Rico, Malaysia
-
GlaxoSmithKlineCompletedMeasles; Mumps; Rubella | Measles-Mumps-Rubella VaccineUnited States, Finland, Taiwan, Estonia, Puerto Rico